ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Kris Discusses Driver Mutations Test False Negatives

Mark G. Kris, MD
Published: Wednesday, Jul 20, 2011



Lead author Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses the false negative rate discovered in the multicenter study focusing on the identification of driver mutations in tumor specimens in patients with lung adenocarcinoma. The study tested patients for KRAS, EGFR, HER2, BRAF, PIK3CA, AKT1, MEK1, and NRAS mutations using standard multiplexed assays and FISH for EML4-ALK rearrangements and MET amplifications.

Kris explains that a bad tissue sample is commonly the cause of false negatives and that measures are being, or are already, in place to assure the biopsy is not from the support structure and from the actual tumor cells. He reassures that false positives are extremely rare and if a test returns positive you can be certain it is accurate.


Lead author Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses the false negative rate discovered in the multicenter study focusing on the identification of driver mutations in tumor specimens in patients with lung adenocarcinoma. The study tested patients for KRAS, EGFR, HER2, BRAF, PIK3CA, AKT1, MEK1, and NRAS mutations using standard multiplexed assays and FISH for EML4-ALK rearrangements and MET amplifications.

Kris explains that a bad tissue sample is commonly the cause of false negatives and that measures are being, or are already, in place to assure the biopsy is not from the support structure and from the actual tumor cells. He reassures that false positives are extremely rare and if a test returns positive you can be certain it is accurate.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x